NASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free PMD Stock Alerts $2.58 +0.02 (+0.78%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.57▼$2.6850-Day Range$2.53▼$3.0552-Week Range$2.06▼$5.15Volume2,952 shsAverage Volume4,602 shsMarket Capitalization$14.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Psychemedics alerts: Email Address Psychemedics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.35% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.22Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.36 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Psychemedics.Read more about Psychemedics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.35% of the float of Psychemedics has been sold short.Short Interest Ratio / Days to CoverPsychemedics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psychemedics has recently decreased by 6.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPsychemedics does not currently pay a dividend.Dividend GrowthPsychemedics does not have a long track record of dividend growth.Read more about Psychemedics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMD. Previous Next 1.0 News and Social Media Coverage News SentimentPsychemedics has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Psychemedics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Psychemedics insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of Psychemedics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.07% of the stock of Psychemedics is held by institutions.Read more about Psychemedics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Psychemedics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Psychemedics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPsychemedics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Psychemedics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Psychemedics Stock (NASDAQ:PMD)Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.Read More PMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMD Stock News HeadlinesMay 17 at 11:11 AM | money.usnews.comPsychemedics Corp.May 16 at 11:33 PM | investing.comPsychemedics (PMD) Earnings Dates & ReportsMay 14, 2024 | msn.comPMD Stock Earnings: Psychemedics Reported Results for Q1 2024May 14, 2024 | sfgate.comPsychemedics: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comPsychemedics Corporation Reports First Quarter 2024 Financial ResultsApril 25, 2024 | finance.yahoo.comPsychemedics Corporation (PMD) Stock Price, News, Quote & History - Yahoo FinanceMarch 28, 2024 | investorplace.comPMD Stock Earnings: Psychemedics Reported Results for Q4 2023March 28, 2024 | globenewswire.comPsychemedics Corporation Reports 2023 Financial ResultsMarch 21, 2024 | globenewswire.comPsychemedics Recognized as a Top 10 Employee Health Testing Services ProviderJanuary 3, 2024 | bizjournals.comSmall cap drug testing company relocates HQ to DFW from MassachusettsJanuary 2, 2024 | msn.comMassachusetts drug testing firm targeting fentanyl relocates corporate HQ to DallasJanuary 2, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Relocation of Headquarters to Dallas, TexasNovember 10, 2023 | msn.comPsychemedics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comPsychemedics Corporation Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | morningstar.comPsychemedics Corp PMDOctober 27, 2023 | finance.yahoo.comUnveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug ScreenSeptember 26, 2023 | benzinga.comPsychemedics Chief Revenue Officer Awarded $448K Worth of Stock OptionsSeptember 22, 2023 | benzinga.comPsychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue OfficerSeptember 21, 2023 | msn.comDo You Get PMS? You Could Be Headed for Early Menopause, Study ShowsAugust 22, 2023 | benzinga.comPresident & CEO at Psychemedics Acquires Company Stock Options Worth 300,000 SharesAugust 18, 2023 | finance.yahoo.comPsychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2023 | marketwatch.comPsychemedics 2Q Loss Widens Amid Labor Shortage, SettlementAugust 11, 2023 | marketwatch.comPsychemedics Eliminates DividendAugust 11, 2023 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2023 Financial ResultsJuly 12, 2023 | marketwatch.comPsychemedics Taps Brian Hullinger as Successor of Long-Time CEO Ray KubackiSee More Headlines Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/19/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PMD CUSIPN/A CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees116Year Founded1985Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net Margins-20.23% Pretax Margin-16.10% Return on Equity-59.21% Return on Assets-32.38% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.45 Sales & Book Value Annual Sales$22.10 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book2.39Miscellaneous Outstanding Shares5,806,000Free Float4,413,000Market Cap$14.98 million OptionableNot Optionable Beta0.69 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Brian Hullinger (Age 56)President, CEO & Director Comp: $361.37kMs. Daniella Mehalik (Age 34)Vice President of Finance Comp: $126.41kMs. Shannon ShoemakerChief Revenue OfficerDr. Werner A. Baumgartner Ph.D.FounderMs. Annette BaumgartnerFounderMr. Michael Weisenhoff (Age 34)Principal Financial & Accounting Manager Mr. Patrick J. Kinney Jr.SecretaryMore ExecutivesKey CompetitorsCentogeneNASDAQ:CNTGBioNexus Gene LabNASDAQ:BGLCDermTechNASDAQ:DMTKOpGenNASDAQ:OPGNExagenNASDAQ:XGNView All CompetitorsInsidersCharles M DoucotSold 12,700 sharesTotal: $59,182.00 ($4.66/share)View All Insider Transactions PMD Stock Analysis - Frequently Asked Questions How have PMD shares performed in 2024? Psychemedics' stock was trading at $2.96 on January 1st, 2024. Since then, PMD shares have decreased by 12.8% and is now trading at $2.58. View the best growth stocks for 2024 here. When is Psychemedics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our PMD earnings forecast. How were Psychemedics' earnings last quarter? Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.12) EPS for the quarter. The company earned $5.36 million during the quarter. Psychemedics had a negative net margin of 20.23% and a negative trailing twelve-month return on equity of 59.21%. Is Psychemedics a good dividend stock? Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for PMD. What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO? 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG). How do I buy shares of Psychemedics? Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.